MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.ebiom.2024.105334

Медицинская библиотека · EBioMedicine · 2024

Potential immunomodulatory effects of CAS+IMD monoclonal antibody cocktail in hospitalized patients with COVID-19.

Wang Bei, Golubov Jacquelynn, Oswald Erin M, Poon Patrick, Wei Qiaozhi, Lett Clarissa, Shehadeh Fadi, Kaczynski Matthew, Felix Lewis Oscar, Mishra Biswajit, Mylona Evangelia K, Wipperman Matthew F, Chio Erica, Hamon Sara C, Hooper Andrea T, Somersan-Karakaya Selin, Musser Bret J, Petro Christopher D, Hamilton Jennifer D, Sleeman Matthew A, Kalliolias George D, Mylonakis Eleftherios, Skokos Dimitris

СтатьяМногоцентровое исследованиеПеревод пока не подготовлен

Аннотация

BACKGROUND

Passive administration of SARS-CoV-2 neutralizing monoclonal antibodies (mAbs), such as CAS + IMD (Casirivimab + Imdevimab) antibody cocktail demonstrated beneficial effects on clinical outcomes in hospitalized patients with COVID-19 who were seronegative at baseline and outpatients. However, little is known about their impact on the host immunophenotypes.

METHODS

We conducted an immunoprofiling study in 46 patients from a single site of a multi-site trial of CAS + IMD in hospitalized patients. We collected longitudinal samples during October 2020 ∼ April 2021, prior to the emergence of the Delta and Omicron variants and the use of COVID-19 vaccines. All collected samples were analyzed without exclusion and post-hoc statistical analysis was performed. We examined the dynamic interplay of CAS + IMD with host immunity applying dimensional reduction approach on plasma proteomics and high dimensional flow cytometry data.

FINDINGS: Using an unbiased clustering method, we identified unique immunophenotypes associated with acute inflammation and disease resolution. Compared to placebo group, administration of CAS + IMD accelerated the transition from an acute inflammatory immunophenotype, to a less inflammatory or "resolving" immunophenotype, as characterized by reduced tissue injury, proinflammatory markers and restored lymphocyte/monocyte imbalance independent of baseline serostatus. Moreover, CAS + IMD did not impair the magnitude or the quality of host T cell immunity against SARS-CoV-2 spike protein.

INTERPRETATION: Our results identified immunophenotypic changes indicative of a possible SARS-CoV-2 neutralizing antibodies-induced anti-inflammatory effect, without an evident impairment of cellular antiviral immunity, suggesting that further studies of Mabs effects on SAS-CoV-2 or other viral mediated inflammation are warranted.

FUNDING: Regeneron Pharmaceuticals Inc and federal funds from the Department of Health and Human Services; Administration for Strategic Preparedness and Response; Biomedical Advanced Research and Development Authority, under OT number: HHSO100201700020C.

Для цитирования: Wang Bei, Golubov Jacquelynn, Oswald Erin M, Poon Patrick, Wei Qiaozhi, Lett Clarissa, Shehadeh Fadi, Kaczynski Matthew, Felix Lewis Oscar, Mishra Biswajit, Mylona Evangelia K, Wipperman Matthew F, Chio Erica, Hamon Sara C, Hooper Andrea T, Somersan-Karakaya Selin, Musser Bret J, Petro Christopher D, Hamilton Jennifer D, Sleeman Matthew A, Kalliolias George D, Mylonakis Eleftherios, Skokos Dimitris. Potential immunomodulatory effects of CAS+IMD monoclonal antibody cocktail in hospitalized patients with COVID-19.. EBioMedicine. 2024. DOI: 10.1016/j.ebiom.2024.105334.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.